Literature DB >> 14530782

Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study.

Feng-Yee Chang1, James E Peacock, Daniel M Musher, Patricia Triplett, Brent B MacDonald, Joseph M Mylotte, Alice O'Donnell, Marilyn M Wagener, Victor L Yu.   

Abstract

Staphylococcus aureus bacteremia is associated with substantial morbidity. Recurrence is common, but incidence and risk factors for recurrence are uncertain. The emergence of methicillin resistance and the ease of administering vancomycin, especially in patients who have renal insufficiency, have led to reliance on this drug with the assumption that it is as effective as beta-lactam antibiotics, an assumption that remains open to debate. We initiated a multicenter, prospective observational study in 6 university hospitals and enrolled 505 consecutive patients with S. aureus bacteremia. All patients were monitored for 6 months and patients with endocarditis were followed for 3 years. Recurrence was defined as return of S. aureus bacteremia after documentation of negative blood cultures and/or clinical improvement after completing a course of antistaphylococcal antibiotic therapy. All blood isolates taken from patients with recurrent bacteremia underwent pulsed-field gel electrophoresis testing. Recurrence was subclassified as reinfection (different pulsed-field gel electrophoresis patterns) or relapse (same pulsed-field gel electrophoresis pattern).Forty-two patients experienced 56 episodes of recurrence (79% were relapses and 21% were reinfection). Relapse occurred earlier than reinfection (median, 36 versus 99 d, p < 0.06). Risk factors for relapse of S. aureus bacteremia included valvular heart disease, cirrhosis of the liver, and deep-seated infection (including endocarditis). Nafcillin was superior to vancomycin in preventing bacteriologic failure (persistent bacteremia or relapse) for methicillin-susceptible S. aureus (MSSA) bacteremia. Failure to remove infected intravascular devices/catheters and vancomycin therapy were common factors in patients experiencing multiple (greater than 2) relapses. However, by multivariate analysis, only endocarditis and therapy with vancomycin (versus nafcillin) were significantly associated with relapse. Recurrences occurred in 9.4% of S. aureus bacteremias following antistaphylococcal therapy, and most were relapses. Duration of antistaphylococcal therapy was not associated with relapse, but type of antibiotic therapy was. Nafcillin was superior to vancomycin in efficacy in patients with MSSA bacteremia.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14530782     DOI: 10.1097/01.md.0000091184.93122.09

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


  134 in total

1.  In vitro killing of community-associated methicillin-resistant Staphylococcus aureus with drug combinations.

Authors:  Samuel A Shelburne; Daniel M Musher; Kristina Hulten; Heather Ceasar; Michael Y Lu; Imran Bhaila; Richard J Hamill
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

2.  Clinical impact of a real-time PCR assay for rapid identification of staphylococcal bacteremia.

Authors:  Abigail M Frye; Catherine A Baker; D Leif Rustvold; Kim A Heath; Jessica Hunt; James E Leggett; Margret Oethinger
Journal:  J Clin Microbiol       Date:  2011-11-09       Impact factor: 5.948

3.  Impact of inadequate empirical therapy on the mortality of patients with bloodstream infections: a propensity score-based analysis.

Authors:  Pilar Retamar; María M Portillo; María Dolores López-Prieto; Fernando Rodríguez-López; Marina de Cueto; María V García; María J Gómez; Alfonso Del Arco; Angel Muñoz; Antonio Sánchez-Porto; Manuel Torres-Tortosa; Andrés Martín-Aspas; Ascensión Arroyo; Carolina García-Figueras; Federico Acosta; Juan E Corzo; Laura León-Ruiz; Trinidad Escobar-Lara; Jesús Rodríguez-Baño
Journal:  Antimicrob Agents Chemother       Date:  2011-10-17       Impact factor: 5.191

4.  Rapid identification of bacteria from positive blood culture bottles by use of matrix-assisted laser desorption-ionization time of flight mass spectrometry fingerprinting.

Authors:  Martin Christner; Holger Rohde; Manuel Wolters; Ingo Sobottka; Karl Wegscheider; Martin Aepfelbacher
Journal:  J Clin Microbiol       Date:  2010-03-17       Impact factor: 5.948

Review 5.  Mechanisms of resistance and clinical relevance of resistance to β-lactams, glycopeptides, and fluoroquinolones.

Authors:  Louis B Rice
Journal:  Mayo Clin Proc       Date:  2012-02       Impact factor: 7.616

6.  Surveillance and management of all types of Staphylococcus aureus bacteraemia.

Authors:  John Paul
Journal:  BMJ       Date:  2006-08-05

7.  Intra- and extracellular activities of dicloxacillin and linezolid against a clinical Staphylococcus aureus strain with a small-colony-variant phenotype in an in vitro model of THP-1 macrophages and an in vivo mouse peritonitis model.

Authors:  Anne Sandberg; Sandrine Lemaire; Françoise Van Bambeke; Paul M Tulkens; Diarmaid Hughes; Christof von Eiff; Niels Frimodt-Møller
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

8.  Outcome of vancomycin treatment in patients with methicillin-susceptible Staphylococcus aureus bacteremia.

Authors:  Sung-Han Kim; Kye-Hyung Kim; Hong-Bin Kim; Nam-Joong Kim; Eui-Chong Kim; Myoung-don Oh; Kang-Won Choe
Journal:  Antimicrob Agents Chemother       Date:  2007-11-05       Impact factor: 5.191

9.  Inhibitory activities of 11 antimicrobial agents and bactericidal activities of vancomycin and daptomycin against invasive methicillin-resistant Staphylococcus aureus isolates obtained from 1999 through 2006.

Authors:  Robert L Holmes; James H Jorgensen
Journal:  Antimicrob Agents Chemother       Date:  2007-11-26       Impact factor: 5.191

10.  Prevalence and outcomes of antimicrobial treatment for Staphylococcus aureus bacteremia in outpatients with ESRD.

Authors:  Kevin E Chan; H Shaw Warren; Ravi I Thadhani; David J R Steele; Jeffrey L Hymes; Franklin W Maddux; Raymond M Hakim
Journal:  J Am Soc Nephrol       Date:  2012-08-16       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.